Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
Cibil Report
Get cibil report
My Account
Log In
Log into your account
Offers
Check out pre-approved offers now!
Languages
Chosen Language: English
Do Not Call
Do not call
En
Viyash Scientific Ltd. Share Price
N/A
1D
1M
3M
6M
1Y
5Y
Day's Range
Day's Range
Low
₹262.25
High
₹271.90
Price Summary
| Previous Close | ₹264.55 |
|---|---|
| Day's Range | ₹262.25 - ₹271.90 |
| Open | ₹266.75 |
| 52 Week Range | ₹166.00 - ₹298.00 |
| Volume | 16,18,461 |
| Market Cap | ₹0.01 |
| Previous Close | ₹264.70 |
|---|---|
| Day's Range | ₹263.00 - ₹271.25 |
| Open | ₹266.80 |
| 52 Week Range | ₹166.20 - ₹297.90 |
| Volume | 85,506 |
| Market Cap | ₹0.01 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 4,337.24 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 65.23 |
| TTM EPS (₹) | 4.06 |
| P/E Ratio | 45.14 |
| Book Value(₹) | 4.27 |
| PAT Margin (%) | 6.57 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 13.10 |
| Trade Value ( ₹ in Lacs) | 229.91 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 65.23 |
| TTM EPS (₹) | 4.06 |
| P/E Ratio | 45.14 |
| Book Value(₹) | 4.27 |
| PAT Margin (%) | 6.57 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 13.10 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 7723.1 | 13103.4 |
| Expenses | N/A | N/A |
| PBT | -366.6 | 491.7 |
| Operating profit | 0.0 | 0.0 |
| Net profit | -321.8 | 584.9 |
About Viyash Scientific Ltd.
| Founded | 1985 |
|---|---|
| Managing Director | Haribabu Bodepudi |
| NSE Symbol | VIYASH |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,69,381.90 | 1,956.30 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,94,374.77 | 7,321.95 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,90,307.55 | 5,004.90 | 3,468.00 - 3,468.00 |
| Apollo Hospitals Enterprise Ltd. | 1,28,113.57 | 8,949.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,16,446.86 | 1,435.75 | 1,165.70 - 1,165.70 |
| Zydus Lifesciences Ltd. | 1,14,378.78 | 1,150.00 | 835.50 - 835.50 |
| Lupin Ltd. | 1,13,316.52 | 2,478.30 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 1,07,245.00 | 1,101.60 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 1,05,978.90 | 2,566.10 | 1,909.70 - 1,909.70 |
| Dr. Reddy's Laboratories Ltd. | 1,02,105.89 | 1,224.45 | 1,148.40 - 1,148.40 |
No Records Found
Latest News
Jun
11
2026
Posted on Jun 11th 2026
Viyash Scientific informs about analyst meet outcome
Pursuant to Regulation 30 of the SEBI Listing Regulations, Viyash Scientific has informed that the audio recording of the earnings call held on May 16, 2024, in connection with the Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2024, is available on the Company's website at the following link: https://viyash.com/static/media/Quarterly_Financial_51.2136fe254b5f83b19e13.mp3 The said disclosure, along with the audio recording link, had been submitted to the National Stock Exchange of India Limited on July 15, 2024. The present submission is being made to facilitate dissemination of the said information on the BSE platform, in line with the communication received from the stock exchange.
The above information is a part of company’s filings submitted to BSE.
Read More
Jun
8
2026
Posted on Jun 8th 2026
Viyash Scientific informs about acquisition
Pursuant to Regulation 30 read with Schedule III of the SEBI Listing Regulations, Viyash Scientific has informed that, Alivira Animal Health Limited, Ireland, step-down wholly owned subsidiary of the Company, has entered into a binding agreement today i.e. June 8, 2026, for the acquisition of 100% shareholding of BioForLife Italia s.r.l., Milan, Italy. The aggregate consideration for the transaction is EUR 16.975 million, structured as follows: a. EUR 15.0 million payable at closing; and b. EUR 1.975 million as deferred consideration, in accordance with the terms of the transaction documents. The transaction is subject to fulfilment of the applicable conditions precedent and receipt of such statutory and regulatory approvals as are applicable to the transaction. The details required under Regulation 30 of the SEBI Listing Regulations read with the applicable SEBI circulars are enclosed as Annexure I.
The above information is a part of company’s filings submitted to BSE.
Read More
May
12
2026
Posted on May 12th 2026
Viyash Scientific submits analyst meet intimation
Pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Viyash Scientific has informed that the Company has scheduled a conference call with the Analysts/Investors on Wednesday, May 20, 2026, at 4.00 pm (IST) to discuss its Q4FY26 financial results. The Conference call details are enclosed. The above details are also available on the website of the Company in the Investors Section at: www.viyash.com
The above information is a part of company’s filings submitted to BSE.
Read More
May
12
2026
Posted on May 12th 2026
Viyash Scientific informs about board meeting
Viyash Scientific has informed that the meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, May 19, 2026, to consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2026; recommend dividend, if any, on the equity shares of the Company for the year ended March 31, 2026.
The above information is a part of company’s filings submitted to BSE.
Read More
Apr
22
2026
Posted on Apr 22nd 2026
Viyash Scientific informs about outcome of board meeting
Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations), Viyash Scientific has informed that the Board of Directors of the Company, at its meeting held today: (a) Approved the appointment of Amit Jain (DIN: 06917608) as an Additional Director (Non-Executive, Non-Independent) of the Company; (b) Approved the appointment of Abhiroop Jayanthi (DIN: 10354445) as an Additional Director (Non- Executive, Non-Independent) of the Company; and (c) Approved revised ESOP Pool Viyash Scientific Limited Employee Stock Option Scheme 2026 (ESOP 2026).
The above information is a part of company’s filings submitted to BSE.
Read More
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Viyash Scientific Ltd. is ₹264.55 as of 2026-07-20.
The market capitalisation of Viyash Scientific Ltd. is ₹11,564.09 as of 2026-07-20.
The 1-year return of Viyash Scientific Ltd. is % as of .
The P/E ratio of Viyash Scientific Ltd. is 45.14 as of 2026-07-21.
The 52-week high and low of Viyash Scientific Ltd. are ₹298.00 and ₹166.00, respectively, as of 2026-07-20.
View More
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
Home
Shopping
Loan Offers
My Accounts
Explore
